Analysis And Perspectives

On October 13 2023, the FDA has granted approval for Pfizer’s ulcerative colitis treatment, Etrasimod, under the brand name Velsipity.

Allergies are on the rise globally, affecting millions of people and significantly impacting their quality of life. The ability to accurately diagnose and manage allergies is crucial for both patients and healthcare providers. With the rising prevalence of allergy, the demand for Allergy Diagnostics has increased m...

Rare eye diseases can pose burden on patients. Top rare eye diseases are Stargardt Disease, Retinitis Pigmentosa, LHON, Retinoblastoma, LSCD

On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.

Immunomodulators are reshaping the healthcare market outlook with their diverse benefits and applications, thereby improving health outcomes.

FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.

Since scopolamine transdermal patch FDA approval, no other treatments approved in US for nausea and vomiting induced by motion sickness.

Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...

Despite facing significant setbacks, companies such as Eli Lilly, BioVie, and others are developing effective Alzheimer's disease treatments.

With rise of gene therapy and other innovative therapeutic approaches, we experience profound change in Netherton syndrome treatment space.